Advancements in the Management of Gynecological Cancers: ESMO 2024 - Episode 7

Antibody-Drug Conjugates in Ovarian Cancer: Emerging Data and Treatment Integration

, , , ,

Panelists discuss recent data on various antibody-drug conjugates (ADCs) in ovarian cancer, including mirvetuximab soravtansine from trials like FORWARD II, MIRASOL, and PICCOLO; luveltamab tazevibulin and rinatabart sesutecan from STRO-002-GM1 and REFRαME-O1; and raludotatug deruxtecan from REJOICE-Ovarian01, highlighting the evolving role of these agents in the treatment landscape for ovarian cancer.

Current Time 0:00
Duration 6:35
Loaded: 0%
Stream Type LIVE
Remaining Time 6:35
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
EP. 1: Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer
EP. 2: Key Findings from the PRIMA Trial: Niraparib in 1L Maintenance for Advanced Ovarian Cancer
EP. 3: Duration of PARP Inhibitor Maintenance Therapy for Ovarian Cancer
EP. 4: Emerging Combinations in Maintenance Therapy for Ovarian Cancer
EP. 5: Optimizing Ovarian Cancer Care: PARP Resistance, Management of Oligoprogression, and Adverse Event Mitigation
EP. 6: Use of Trastuzumab Deruxtecan in Ovarian Cancer
Now Viewing
EP. 7: Antibody-Drug Conjugates in Ovarian Cancer: Emerging Data and Treatment Integration
EP. 8: Navigating Treatment Strategies for Advanced Cervical Cancer: Localized Therapy, KEYNOTE-A18 Trial Data, and Frontline Approaches
EP. 9: Integrating Tisotumab Vedotin into Ovarian Cancer Therapy
EP. 10: Biomarker Testing in Advanced Endometrial Cancer: Approach, Key Markers, and Impact on Treatment Decisions
EP. 11: Managing Recurrent Endometrial Cancer: Treatment Strategies and RUBY Trial Insights
EP. 12: Durvalumab in Endometrial Cancer: DUO-E Trial Updates
EP. 13: Innovative Combination Strategies for Endometrial Cancer: Updates from LEAP and KEYNOTE-B21 Trials
EP. 14: T-DXd in Advanced Endometrial Cancer
EP. 15: Emerging ADCs in Advanced Endometrial Cancer: Anti-TROP2 and Anti-FR Agents

Video content above is prompted by the following:

  • Briefly comment on recent data surrounding other antibody-drug conjugates in ovarian cancer and discuss the evolving role of these agents in the treatment landscape.
  • Mirvetuximab soravtansine (anti-FR) 
  • FORWARD II; MIRASOL; PICCOLO
  • Luveltamab tazevibulin (anti-FR), rinatabart sesutecan (Rina-S)
  • STRO-002-GM1; REFRαME-O1
  • Rina-S
  • Raludotatug deruxtecan (R-DXd, anti-CDH6)
  • REJOICE-Ovarian01 
x